TCT 2024 - TCTMD.com
Oct 27, 2024 · Impact of MitraClip on Hospitalization Rates in Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation: Insights From RESHAPE-HF2
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
What’s Going to Be Big at TCT 2024? - tctmd.com
Oct 17, 2024 · One of the major themes of this year’s meeting is intervening earlier to prevent disease, including with TAVI in aortic stenosis.
Cheaper Version of Tirzepatide for Weight Loss Now Available
Aug 28, 2024 · Tirzepatide, when used for weight loss under the brand name Zepbound, is now more affordable thanks to a self-pay option created by the manufacturer, Lilly. The discount is …
Coronary CTA Reimbursement for US Hospitals to Double in 2025
Nov 8, 2024 · For once, cardiologists find good news in the US Centers for Medicare & Medicaid Services (CMS) annual Hospital Outpatient Prospective Payment System (HOPPS) final rule: …
Will Semaglutide Change Cardiac Surgery? It Already Has
Oct 10, 2024 · The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.
QFR No Match for FFR in Guiding Revascularizations: FAVOR III …
Oct 30, 2024 · WASHINGTON, DC—As a guide for deciding whether to revascularize patients with intermediate coronary stenoses, quantitative flow ratio (QFR) isn’t able to match fractional …
Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 …
Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released …
EARLY TAVR Breaks New Ground for Preemptive Treatment of …
Oct 28, 2024 · (UPDATED) While discussions about the lack of a mortality effect will continue, some say the findings may be enough to change guidelines.
Micra Leadless Pacemaker Performs Well Through 5 Years
Mar 6, 2024 · The Micra VR leadless pacemaker (Medtronic) continues to have a good safety and efficacy profile through the 5-year mark, according to real-world registry data. Rates of major …